Clinical trials: Cancer Disease Progression
Metastatic Breast Cancer
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
Target Population: female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy.
- Trial name
- NCT01477060
- Testing
- Lapatinib, Metformin
- Where
- 11 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione Michelangelo
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Prostate Cancer
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967889
- Testing
- gene expression analysis, protein analysis, biologic sample preservation procedure
- Where
- United Kingdom
- Sponsor
- Cancer Research UK
Prostate Cancer
BN83495 in Prostate Cancer
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy
- Trial name
- STX64PC (NCT00790374)
- Testing
- BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Ipsen
Gastric Cancer
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
The aim of this study is to evaluate the efficacy and safety of combination therapy with ramucirumab, paclitaxel, and trastuzumab biosimilar as second line treatment of HER2 positive metastatic gastric cancer after failure of…
- Trial name
- NCT03766607
- Testing
- Trastuzumab, Ramucirumab, Paclitaxel
- Where
- South Korea
- Sponsor
- Korean South West Oncology Group
Progression of Prostate Cancer
FOcal RECurrent Assessment and Salvage Treatment
Radiotherapy is the commonest form of prostate cancer treatment in the UK. In one in four men, radiotherapy will fail to control the cancer. These men are offered hormonal treatment which has significant side effects.
- Trial name
- FORECAST (NCT01883128)
- Testing
- Whole Body MRI, Focal Salvage Therapy, MRI Targeted biopsies
- Where
- 2 sites in United Kingdom
- Volunteers
- 177 people
- Sponsor
- University College London Hospitals
Advanced Gastrointestinal Stromal Tumor
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
- Trial name
- NCT00254267
- Testing
- AMG 706
- Volunteers
- 35 people
- Sponsor
- Amgen
Colorectal Cancer
Evaluation of Serum Tumor Endothelial Marker1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression
Aim of work 1. measurement level of serumTEM1 in CRC patients by ng/ml using ELISA kits . 2. find relation between serum TEM1 level and staging of CRC patients . 3.
- Trial name
- NCT05779553
- Testing
- Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis.
- Conditions
- Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical
- Trial name
- NCT06487481
- Testing
- Surgical resection, Preoperative RT
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
To investigate safety and efficacy of single agent sunitinib malate in Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor.
- Trial name
- GIST (NCT00793871)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Esophageal Cancer
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Esophageal cancer is one of the most common malignant tumors worldwide, with high invasiveness and lethality. Currently, the treatment for resectable locally advanced esophageal cancer mainly consists of a treatment model…
- Trial name
- NCT06889402
- Testing
- Neoadjuvant therapy with PD-L1 inhibitor
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Neoplasms, Advanced Breast Cancer
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
This is a single-arm, open-label, phase 2 clinical trial using a stratified Simon minimax two-stage design. The study aims to evaluate the efficacy and safety of low-dose apatinib (250 mg daily) combined with physician-selected…
- Conditions
- Breast Neoplasms, Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-low Breast Cancer
- Trial name
- NCT07907354
- Testing
- Apatinib mesylate, Physician's choice chemotherapy
- Volunteers
- 56 people
- Sponsor
- Yunnan Cancer Hospital
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer.
- Trial name
- NCT00520403
- Testing
- bevacizumab [Avastin], Interferon alfa-2a, Vinblastine
- Where
- 16 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer, Neoadjuvant Therapy
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Background There is currently no reliable means to restage rectal cancers after neoadjuvant chemoradiation. There are still no reliable methods to identify patients with pCR before radical surgery.
- Conditions
- Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
- Trial name
- BIOPSY (NCT04743102)
- Testing
- multi-points and full-thickness Biopsy, traditional cCR
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Beijing Chao Yang Hospital
Metastatic Melanoma
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited.
- Trial name
- NCT05510466
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Montpellier
Prostatic Neoplasms
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Primary Objective: Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: Describe treatment patterns Describe the characteristics and outcomes of patients…
- Trial name
- PORTREAT (NCT01076751)
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Progression, Survival
PD-L1 Expression in Advanced Osteosarcoma
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment.
- Trial name
- NCT03582527
- Testing
- all study participants
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Metastatic Melanoma
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease.
- Trial name
- NCT01340729
- Testing
- TPI 287
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer Metastatic
Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone
This study is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer.
- Trial name
- NCT03988686
- Testing
- Radical prostatectomy plus standard care, Standard of care for metastatic prostate cancer
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Non-muscle Invasive Bladder Cancer, Cystoscopy
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across…
- Conditions
- Non-muscle Invasive Bladder Cancer, Cystoscopy, Recurrence, Progression
- Trial name
- NCT06235853
- Testing
- Blood serum: sUPAR, PAI-1, IL-8., Urine: IL-8, APOE, VEGF.
- Where
- Poland
- Volunteers
- 240 people
- Sponsor
- Wroclaw Medical University